NARA Discovery
Article Details
← Back to Search Results
Journal Article

Continuous home cage monitoring of activity and sleep in mice during repeated paroxetine treatment and discontinuation

Helen M. Collins; Raquel Pinacho; S. K. Eric Tam; Trevor Sharp; David M. Bannerman; Stuart N. Peirson
Psychopharmacology · Vol. 240, Issue 11 · pp. 2403-2418 · 2023

Abstract

Rationale Non-invasive home cage monitoring is emerging as a valuable tool to assess the effects of experimental interventions on mouse behaviour. A field in which these techniques may prove useful is the study of repeated selective serotonin reuptake inhibitor (SSRI) treatment and discontinuation. SSRI discontinuation syndrome is an under-researched condition that includes the emergence of sleep disturbances following treatment cessation. Objectives We used passive infrared (PIR) monitoring to investigate changes in activity, sleep, and circadian rhythms during repeated treatment with the SSRI paroxetine and its discontinuation in mice. Methods Male mice received paroxetine (10 mg/kg/day, s.c. ) for 12 days, then were swapped to saline injections for a 13 day discontinuation period and compared to mice that received saline injections throughout. Mice were continuously tracked using the Continuous Open Mouse Phenotyping of Activity and Sleep Status (COMPASS) system. Results Repeated paroxetine treatment reduced activity and increased behaviourally-defined sleep in the dark phase. These effects recovered to saline-control levels within 24 h of paroxetine cessation, yet there was also evidence of a lengthening of sleep bouts in the dark phase for up to a week following discontinuation. Conclusions This study provides the first example of how continuous non-invasive home cage monitoring can be used to detect objective behavioural changes in activity and sleep during and after drug treatment in mice. These data suggest that effects of paroxetine administration reversed soon after its discontinuation but identified an emergent change in sleep bout duration, which could be used as a biomarker in future preclinical studies to prevent or minimise SSRI discontinuation symptoms.

Bibliographic Information

JournalPsychopharmacology
PublisherSpringer
Publication Date2023-11-01
Publication Year2023
Volume240
Issue11
Pages2403-2418
Document TypeJournal Article
Print ISSN0033-3158
eISSN1432-2072
DOI10.1007/s00213-023-06442-3

Access Information

NARA Access Coverage1959-01-01~Current
Journal Homepagehttps://www.springer.com/journal/213
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.